Kounis syndrome moves from rare curiosity to a defined allergic coronary syndrome
Kounis syndrome is increasingly difficult to dismiss as a diagnostic oddity. The 2026 review places Kounis syndrome squarely in the center of allergic acute coronary syndromes, where an acute hypersensitivity reaction can trigger ischemia through coronary vasospasm, plaque thrombosis, stent thrombosis, or graft involvement. In practical terms, the syndrome links mast cell activation and inflammatory mediator release to sudden coronary instability, making allergy and cardiology collide at the bedside.
The review argues that the most common presentation remains the vasospastic form, but the clinical frame is broader than the classic epicardial spasm narrative. Coronary vasomotor dysfunction, including microvascular involvement, may account for many patients whose angiograms do not show a fixed obstructive lesion. A normal or non-obstructive coronary tree does not exclude a coronary event when the trigger is allergic and the vasomotor response is severe.
Mediator release explains why the coronary circulation fails during allergy
The biological logic is straightforward even if the presentation is not. During an allergic or hypersensitivity episode, immune cell activation releases vasoactive and prothrombotic mediators that can constrict coronary smooth muscle, destabilize plaque, and promote thrombosis. In type I Kounis syndrome, the coronary artery itself may be structurally normal, yet the spasm can still be intense enough to produce chest pain, electrocardiographic changes, and myocardial injury. In type II and type III disease, the same inflammatory surge acts on a more vulnerable substrate: atherosclerotic plaque or a coronary stent. Type IV extends the syndrome to bypass grafts.
This mechanistic breadth matters because it explains why the syndrome does not fit neatly into a single ischemic pathway. Some patients present as if they have classic vasospastic angina. Others look like acute coronary syndrome with biomarker elevation, yet angiography reveals little or no epicardial obstruction. The review emphasizes that this disconnect is not a contradiction; it is the central feature of the syndrome’s biology.
A sudden allergic trigger can therefore produce a coronary event without leaving the familiar angiographic fingerprint of a large-artery occlusion.
Normal angiography does not rule out ischemia in the allergic setting
One of the strongest points in the review is the gap between clinical suspicion and angiographic yield. Epicardial coronary spasm is documented in only a minority of patients, while normal or non-obstructive coronary arteries are frequently seen. That pattern pushes the diagnostic conversation beyond the coronary angiogram alone and toward a broader physiologic model.
Emerging evidence from provocative testing, invasive coronary functional assessment, cardiac magnetic resonance, and nuclear imaging suggests that coronary microvascular dysfunction may contribute substantially to the clinical phenotype. This is an important conceptual shift. A patient may have no major epicardial obstruction, yet still have true ischemia because the microcirculation fails to dilate appropriately or goes into spasm. In allergic ACS, the distal coronary bed may be the actual site of injury.
The review therefore treats Kounis syndrome as more than allergic epicardial vasospasm. It belongs within the MINOCA spectrum when no obstructive culprit lesion is found, particularly in type I disease. That classification has real consequences for how clinicians interpret chest pain, troponin elevation, and transient electrocardiographic abnormalities in the setting of urticaria, bronchospasm, or anaphylaxis.
Diagnostic workup requires more than a single test
The review supports a comprehensive diagnostic approach rather than a narrow, one-step strategy. Signs and symptoms, biochemical findings, electrocardiography, echocardiography, coronary angiography, and multimodality imaging all have a role, with invasive assessment reserved for selected patients. The challenge is not identifying whether the patient is allergic; it is determining whether the allergic reaction has also involved the coronary circulation.
Clinical reasoning starts with timing and context. Chest pain or ischemic changes that emerge during or shortly after an allergic event should raise immediate concern for Kounis syndrome. The presence of cutaneous findings, respiratory symptoms, hypotension, or exposure to a likely trigger strengthens the suspicion. Yet the coronary syndrome can be missed if the evaluation stops after treating the allergy alone, or if clinicians assume that a non-obstructive angiogram excludes ischemia.
Cardiac imaging and functional testing become especially relevant when symptoms and biomarkers suggest myocardial injury but the epicardial anatomy appears unrevealing. The review’s message is blunt: the traditional picture of a single spastic epicardial vessel is too narrow to capture the full disease burden.
Type I disease deserves a place inside MINOCA classifications
The most consequential argument in the review is the call to recognize type I Kounis syndrome as a distinct allergic vasomotor acute coronary syndrome within the MINOCA spectrum. This is not a semantic exercise. Classification shapes diagnostic workup, informs treatment decisions, and influences whether clinicians look for coronary spasm, microvascular dysfunction, or allergic triggers in the first place.
Type I disease is especially likely to be overlooked because it can occur in patients without known coronary artery disease. Yet the absence of plaque does not diminish the severity of the ischemic event. Allergic mediators can still provoke dramatic vasoconstriction and ischemia in an otherwise normal coronary tree. A framework that treats such cases as bona fide MINOCA-compatible events would better reflect the underlying physiology and may improve recognition in routine care.
By contrast, type II, type III, and type IV disease reflect the interaction between allergy and established coronary pathology or implanted hardware. Those variants remind clinicians that hypersensitivity can act as both trigger and amplifier across different coronary substrates.
Treatment decisions remain constrained by incomplete evidence
Therapeutic implications remain incompletely understood, and the review does not pretend otherwise. The central problem is that the same event involves both allergy and ischemia, which can pull treatment in different directions. Managing the allergic reaction is essential, but coronary vasospasm or thrombosis may also need specific cardiovascular therapy. The pathophysiology makes it clear why one-size-fits-all management is unsafe.
The review’s broader clinical lesson is that better recognition should precede better classification, and better classification should precede more precise treatment pathways. Current evidence supports awareness, structured evaluation, and suspicion for coronary involvement when allergic symptoms and ischemic signs overlap. In the vasospastic form, clinicians must think beyond the usual obstructive coronary model and consider vasomotor instability, microvascular dysfunction, and allergic mediator release as part of the same event.
What the review does not provide is a fully validated diagnostic algorithm or a standardized treatment pathway that has been tested across large prospective cohorts. The boundaries of the syndrome, particularly outside classic epicardial spasm, remain incompletely defined. Future guideline work will need to decide whether allergic coronary syndromes deserve a more explicit place in the taxonomies used for acute coronary care.